Michele Cavo, MD, from the Bologna University School of Medicine, Bologna, Italy, discusses two important clinical trials in myeloma at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. The EMN02 (NCT01208766) trial compared a combination of bortezomib, melphalan, and prednisone (VMP) with high dose melphalan as consolidation after autologous stem cell transplantation. Patients in both arms were also randomised to either single or double transplantation. The results showed that patients w underwent a double transplant had a longer progression free survival. The staMINA (NCT01109004) trial, however, gave conflicting results about the efficacy of double transplants, however, Dr Cavo does state that there are differences in the designs of both trials, making them incomparable.